BioAtla, Inc. (NASDAQ:BCAB) Short Interest Update

BioAtla, Inc. (NASDAQ:BCAB - Get Free Report) saw a significant growth in short interest in October. As of October 15th, there was short interest totalling 5,240,000 shares, a growth of 17.2% from the September 30th total of 4,470,000 shares. Based on an average daily trading volume, of 1,180,000 shares, the short-interest ratio is presently 4.4 days.

Analyst Ratings Changes

Separately, JMP Securities restated a "market outperform" rating and set a $5.00 target price on shares of BioAtla in a research report on Monday, September 16th.

Institutional Trading of BioAtla

A number of institutional investors have recently made changes to their positions in BCAB. Price T Rowe Associates Inc. MD bought a new stake in shares of BioAtla in the first quarter worth about $45,000. Vontobel Holding Ltd. bought a new stake in shares of BioAtla in the 3rd quarter worth approximately $28,000. Ground Swell Capital LLC purchased a new position in shares of BioAtla during the second quarter valued at approximately $33,000. Valmark Advisers Inc. bought a new position in shares of BioAtla during the second quarter valued at approximately $34,000. Finally, Rinkey Investments bought a new position in shares of BioAtla during the second quarter valued at approximately $35,000. Hedge funds and other institutional investors own 77.23% of the company's stock.

BioAtla Stock Performance

BioAtla stock traded up $0.10 during mid-day trading on Monday, hitting $2.09. 693,072 shares of the company traded hands, compared to its average volume of 832,884. BioAtla has a one year low of $1.14 and a one year high of $4.02. The stock has a market cap of $100.56 million, a price-to-earnings ratio of -0.84 and a beta of 1.06. The stock has a fifty day moving average price of $1.86 and a 200-day moving average price of $1.91.

BioAtla (NASDAQ:BCAB - Get Free Report) last released its earnings results on Thursday, August 8th. The company reported ($0.44) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.01. During the same quarter in the prior year, the business posted ($0.75) EPS. Sell-side analysts predict that BioAtla will post -1.52 EPS for the current year.

BioAtla Company Profile

BioAtla, Inc, a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.